Drug intelligence / Profile preview

GSK2981710

Development stage: Phase 1
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK2981710 is a medium-chain triglyceride (MCT) formulation developed by GSK for the potential treatment of age-related cognitive decline and Alzheimer's disease. It functions as a ketogenic precursor, intended to elevate plasma levels of ketone bodies such as β-hydroxybutyrate (BHB) to provide an alternative fuel source for neurons in the presence of glucose hypometabolism. In clinical trials, the compound was administered at doses up to 30g/day. While it successfully increased BHB levels, it failed to demonstrate significant improvements in cognitive function or memory-related neuronal activity in healthy older participants. The development appears to have stalled following these results, with gastrointestinal side effects like diarrhea being commonly reported.

Other names: medium-chain triglycerideMCT

Beyond the preview

Go deeper on GSK2981710.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK2981710.

Explore the full profile